Investment Rating - The report maintains a "Buy" rating for the company, indicating a favorable outlook for investment over the next 6-12 months [5]. Core Insights - The company is expanding into new business areas such as AI terminal hardware, commercial satellites, data centers, and robotics, which opens up significant growth potential [1][2]. - The company has successfully entered the North American AI hardware supply chain, providing comprehensive solutions for smart terminal products [2]. - The growth in AI technology is driving demand for the company's core products, including antennas and wireless charging modules [3]. - The company has adjusted its profit forecasts for 2025 and 2026, predicting a decline in net profit due to reduced government subsidies, but expects a recovery in 2027 [4]. Summary by Sections Financial Performance - For Q1-Q3 2025, the company reported revenue of 2.759 billion yuan, a year-on-year increase of 4.20%, and a net profit of 325 million yuan, a decrease of 1.77% [1]. - The gross margin for Q1-Q3 2025 was 21.53%, up 0.73 percentage points year-on-year, with Q3 showing a gross margin of 25.45%, an increase of 1.69 percentage points [1]. Revenue and Profit Forecast - The revenue forecast for 2025 is set at 9.618 billion yuan, with a growth rate of 10.00%, while the net profit is projected at 778 million yuan, reflecting a year-on-year decline of 11% [4]. - The company anticipates a net profit of 998 million yuan in 2027, corresponding to a price-to-earnings (P/E) ratio of 30X [4]. Product Development and Market Position - The company is focusing on high-strength R&D investments in core materials such as polymer, magnetic, ceramic, and thermal materials [3]. - It is actively developing various types of antennas and enhancing its capabilities in wireless charging technologies [3]. Market Dynamics - The global consumer electronics market is recovering, which supports the company's existing business while it explores new opportunities in AI and automotive sectors [1][2].

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Views - The company has shown steady revenue growth, with a 2025Q1-Q3 revenue of 6.67 billion yuan, up 8.8% year-on-year, and a net profit of 1.59 billion yuan, up 9.2% year-on-year [1] - The company is actively expanding its product offerings with differentiated products, including unmanned aerial work platforms and various specialized robots, which helps to mitigate risks associated with reliance on a single industry [3] - The company has successfully increased its overseas revenue by 21.3% year-on-year in 2025H1, despite challenges in the domestic high machine export market [2] Summary by Sections Financial Performance - For 2025Q3, the company reported a revenue of 2.34 billion yuan, a 2.8% increase year-on-year, but a net profit decline of 14.7% [1] - The gross margin for 2025Q3 was 36.1%, down 1.5 percentage points year-on-year but up 4.1 percentage points quarter-on-quarter [1] Product Development - The company has launched a series of differentiated products aimed at new application scenarios, including robots for ship painting and rust removal, tunnel drilling, and glass suction vehicles [3] Market Expansion - The company is focusing on expanding into non-trade friction overseas markets, with a positive outlook for continued growth in overseas revenue due to increased efforts in market development [2] Earnings Forecast - The projected net profits for 2025, 2026, and 2027 are 2.068 billion yuan, 2.407 billion yuan, and 2.753 billion yuan, respectively, with corresponding EPS of 4.08 yuan, 4.75 yuan, and 5.44 yuan [4][5]

晨会速递 分析师点评 市场数据 总量研究 【宏观】美国政府重新开门，市场为何"不买账"？——解构美国系列第十五篇 美国政府开门后，为何市场未定价利好，波动不止？一是停摆"不确定"，本次开门 未解决两党医保分歧，若 12 月延长医保补贴未通过，不排除民主党再度以停摆威胁 共和党让步，明年 1 月政府或再次停摆。二是降息"不确定"，尽管政府开门后经济 数据陆续发布，但 9 月非农数据时效性不足，10 月经济数据或缺失，参考价值不足， 美联储 12 月降息与否将更多依赖 12 月 5 日公布的 11 月非农数据。 行业研究 【钢铁】取向硅钢现货价格年内跌幅达到 23%——金属周期品高频数据周报 （2025.11.10-11.16）（增持） 2025 年 11 月 19 日 投资建议：2025 年 2 月 8 日，工信部出台《钢铁行业规范条件（2025 年版）》，且 7 月 18 日再次提及"推动落后产能有序退出"，我们认为钢铁板块的盈利有望修复 到历史均值水平，钢铁股的 PB 也有望随之修复。但建议防范期货价格大幅波动风险。 风险提示：根据历史数据得出的相关性失效的风险；政府对大宗商品价格调控的风险； 公司经营不善 ...

公司研究 出海并购加速，回购加码彰显发展信心 ——固生堂（2273.HK）事件点评 要点 2025 年 11 月 18 日 事件：1）近期，公司公告附属公司 Gushengtang Singapore 于 2025 年 11 月 16 日与大中堂（DA ZHONG TANG PTE. LTD.）股东订立股权转协议，拟收购 大中堂 100%股权及全部相关权益。2）近期，公司董事会再次决议行使回购授 权，拟新增最多不超过 3 亿港元的回购额度。 点评： 出海并购步伐加快，业务扩张加速。此次对大中堂的收购是继今年 10 月与新 加坡数字医疗平台 1doc 达成战略合作后，固生堂在海外市场实现的又一重要 战略部署，标志着固生堂中医出海战略进入加速落地阶段。大中堂品牌在新加 坡运营 14 家中医门诊部，覆盖多个核心商圈及居民社区，拥有成熟的本地化服 务能力与高度信赖的用户基础。今年以来，固生堂持续加快中医药出海步伐， 采取"并购+合作+自建"三轮驱动策略，积极拓展新加坡市场。对大中堂收购 完成后，固生堂将新增运营 14 家门诊机构，有助于公司快速构建在新加坡的规 模化服务网络，提升区域市场覆盖与运营协同效应。公司持续推 ...

2025 年 11 月 18 日 行业研究 取向硅钢现货价格年内跌幅达到 23% ——金属周期品高频数据周报（2025.11.10-11.16） 要点 流动性：10 月 BCI 中小企业融资环境指数值为 52.41，环比+10.15%。 （1）BCI 中小企业融资环境指数 2025 年 10 月值为 52.41，环比上月 +10.15%；（2）M1 和 M2 增速差与上证指数存在较强的正向相关性：M1 和 M2 增速差在 2025 年 10 月为-2.0 个百分点，环比-0.80 个百分点；（3） 本周伦敦金现价格为 4082 美元/盎司。 基建和地产链条：1-10 月全国房地产新开工面积累计同比为-19.80%。 （1）本周价格变动：螺纹-0.94%、水泥价格指数-0.76%、橡胶+3.14%、焦 炭+0.00%、焦煤+1.86%、铁矿+0.26%；（2）本周全国高炉产能利用率、 水泥、沥青环比分别+0.99pct、-11.30pct、+1.0pct。 地产竣工链条：1-10 月全国商品房竣工面积累计同比为-16.90%。本周钛白 粉、玻璃的价格环比分别+0.00%、+0.00%，玻璃毛利润为-58 元/吨 ...

10 月份财政数据需关注以下三点：其一，一般公共预算支出同比转负，"三保"和 基建投资相关的支出同比增速均较上月回落，需关注 9 月份以来增量财政政策的效 果；其二，政府性基金收支均降速，预计待地方债务结存限额下达并用于补充地方政 府综合财力后，能有所改观；其三，年内政府债供给已至尾声，而 10 月财政存款同 比多增意味着财政资金仍有释放空间，对后续流动性构成利好。风险提示：政策落地 不及预期，重大项目开工不及预期。 行业研究 2025 年 11 月 18 日 晨会速递 分析师点评 市场数据 总量研究 【宏观】财政降速，关注增量政策效能释放——2025 年 10 月财政数据点评 【高端制造】聚变新能发布采购项目超 20 亿元，行业招标提速——可控核聚变行业 系列报告之三(买入) 聚变新能发布招标超 20 亿元，主要涉及电源系统、低温系统、屏蔽包层等环节。"十 五五"规划将核聚变能列为未来产业，可控核聚变产业具备长期增长潜力。建议关注： 1）真空室及内部件：合锻智能、国光电气、安泰科技、应流股份、派克新材、天工 国际（H）；2）磁体系统：联创光电、永鼎股份；3）电源系统：四创电子、王子新 材、旭光电子。4）低温 ...

2025 年 11 月 17 日 总量研究 医药主题基金表现占优，TMT、科创主题 ETF 受被动资金加仓 ——基金市场与 ESG 产品周报 20251117 要点 市场表现综述：大类资产方面，本周（下文如无特殊说明，本周均指代 2025.11.10-2025.11.14）黄金价格上涨，国内权益市场指数集体回调。行业 方面，本周综合、纺织服饰、商贸零售行业涨幅居前，通信、电子、计算机 行业跌幅居前。基金市场方面，本周债券型基金表现占优，股混基金净值回 撤。 基金产品发行情况：本周国内市场新成立基金 25 只，合计发行份额为 141.73 亿份。其中股票型基金 14 只、FOF 基金 4 只、混合型基金 4 只、债 券型基金 3 只。全市场新发行基金 41 只，从类型来看，股票型基金 23 只、 混合型基金 8 只、FOF 基金 5 只、债券型基金 4 只、REITs1 只。 基金产品表现跟踪：长期行业主题基金指数表现来看，本周医药主题基金表 现占优，TMT 主题基金回撤明显。截至 2025 年 11 月 14 日，医药、周期、 消费、金融地产、新能源、行业轮动、行业均衡、国防军工、TMT 主题基金 本周涨跌幅 ...

Investment Rating - The report maintains a rating of "Overweight" for the pharmaceutical and biotechnology sector [5]. Core Insights - The report highlights a significant increase in influenza-like illness (ILI) cases, suggesting a potential surge in demand for flu vaccines, respiratory virus testing, and cold medications [2][24]. - The report emphasizes the importance of clinical value in the pharmaceutical sector, advocating for investments in innovative drug chains and medical devices [3][27]. Summary by Sections Market Review - The pharmaceutical and biotechnology index rose by 3.29%, outperforming the CSI 300 index by 4.37 percentage points and the ChiNext index by 4.59 percentage points, ranking 5th among 31 sub-industries [1][16]. - The Hong Kong Hang Seng Medical Health Index increased by 6.8%, surpassing the Hang Seng Index by 5.4 percentage points [1][16]. Current Trends - The proportion of flu-like cases has been rising, with the ILI percentage reported at 5.5% in southern provinces and 6.1% in northern provinces, indicating a higher incidence compared to previous years [22][23]. - The report warns of a potential severe flu season in 2025, driven by changes in circulating strains and increased risks of immune evasion [2][23]. Investment Recommendations - The report suggests focusing on investment opportunities in flu vaccines, respiratory virus testing, cold medications, and special drugs due to the rising flu cases [2][24]. - Specific companies recommended for flu vaccines include Hualan Biological Engineering, Baike Biological, and Jindike; for respiratory virus testing, companies like Innotec, Shengxiang Biological, and Botao Biological are highlighted; and for cold medications, companies such as Zhongsheng Pharmaceutical, China Resources Sanjiu, and Kangyuan Pharmaceutical are suggested [2][24][26]. Key Company Earnings Forecast and Valuation - The report provides a detailed earnings forecast and valuation table for key companies, indicating a "Buy" rating for Tianjin Tasly Pharmaceutical, Innovent Biologics, and WuXi AppTec, among others [4][29]. - The earnings per share (EPS) and price-to-earnings (PE) ratios for these companies are projected to improve over the next few years, reflecting positive market sentiment [4]. Annual Investment Strategy - The report outlines a three-stage investment strategy focusing on clinical value, emphasizing the need for innovative drugs and high-end medical devices [3][27]. - It highlights the potential for growth in the innovative drug sector and the importance of domestic and international market dynamics [27][28].

Macro Analysis - Consumption continues to recover while investment remains sluggish, with October economic data reflecting significant pressure on year-on-year performance due to last year's "export rush" and policy adjustments [2] - Both goods and service consumption show marginal recovery, corroborated by the October CPI recovery, but manufacturing, real estate, and infrastructure investments continue to decline [2] Market Strategy - The market is expected to maintain a wide fluctuation phase in the short term, despite being in a bull market, with significant room for index growth [3] - Short-term focus should be on defensive and consumer sectors, while mid-term attention should remain on TMT and advanced manufacturing sectors [3] Bond Market Insights - Major indicators in the bond market have seen a decline, with October industrial production growth hitting its lowest for the year [4] - The bond market is expected to become more optimistic as the funding environment remains loose, with a projected 10Y government bond yield fluctuation center at 1.7% [4] - The convertible bond market has seen a new wave of growth, with long-term views on convertible bonds remaining positive due to strong demand [5] Credit Market Overview - The issuance of credit bonds increased by 25.31% week-on-week, with a total of 330 bonds issued amounting to 455.379 billion yuan [7] Banking Sector Analysis - The net profit growth rate of commercial banks improved by 1.2 percentage points compared to the first half of 2025, with state-owned banks showing the highest growth at 2.3% [9] - The overall interest income is expected to remain stable, supported by a recovering capital market, which may sustain the fee income growth trend [9] Real Estate Market Trends - In the first ten months, the new housing transaction area in 30 core cities decreased by 36.9%, while the average transaction price increased by 2% [11] - Recommendations include stable leading companies in core cities and a positive outlook on property service development [11] Steel Industry Developments - The suspension of export restrictions on antimony to the U.S. is expected to boost China's antimony exports [12] Non-Ferrous Metals Sector - The rapid development of data centers in the U.S. is causing power supply tensions, presenting investment opportunities in electrolytic aluminum [13] - Recommendations include companies like Yun Aluminum and China Hongqiao, with a focus on the potential impact of overseas aluminum production capacity [13] Company-Specific Insights - Longxin Group is focusing on digitalization and expanding its business matrix, with projected EPS for 2025, 2026, and 2027 at 0.35, 0.57, and 0.73 yuan respectively [14] - Dama Entertainment's core business is centered on performances and IP derivatives, with net profit forecasts for FY26-FY28 adjusted upwards [15] - Tencent's strong game pipeline and AI strategy are expected to enhance its long-term advertising valuation, with revised net profit forecasts for 2025-2027 [16] - WeRide is positioned as a leader in L4 autonomous driving, with revenue projections for 2025-2027 at 587 million, 1.131 billion, and 2.017 billion yuan [17] - SMIC's Q3 performance exceeded expectations, driven by AI demand and accelerated capacity expansion, with revised profit forecasts for 2025-2027 [18] - Mao Geping's brand growth momentum continues, with significant sales increases during the "Double Eleven" shopping festival [19]

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Insights - The company has launched a restricted stock incentive plan to enhance its long-term development confidence and align the interests of shareholders, the company, and management [1] - The company's performance has been strong, with a 31.3% year-on-year increase in revenue to 2.59 billion yuan and a 36.1% increase in net profit to 670 million yuan in the first half of 2025 [2] - The company is focusing on high-end beauty positioning, expanding its product range into fragrances, and has seen significant growth in both online and offline channels [3] Summary by Sections Company Performance - In the first half of 2025, the company achieved revenue of 2.59 billion yuan, a 31.3% increase year-on-year, and a net profit of 670 million yuan, up 36.1% [2] - Sales on major platforms during the "Double Eleven" shopping festival showed strong growth, with year-on-year increases of 60.5% on Taobao, 39.8% on Douyin, and 22.3% on JD [2] Product and Market Strategy - The company is enhancing its high-end beauty positioning and has expanded its product categories to include fragrances, with successful product launches in various high-end department stores [3] - The product matrix has been enriched with new series such as Guo Yun Ning Xiang and Wen Dao Dong Fang [3] Financial Forecast - The company forecasts net profits of 1.21 billion yuan, 1.58 billion yuan, and 2.04 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 2.46 yuan, 3.22 yuan, and 4.16 yuan [3][10] - The current stock price corresponds to a PE ratio of 34, 26, and 20 for the years 2025, 2026, and 2027 respectively [3][10]